Federal judge in Delaware entered judgment confirming a jury verdict against RA Capital Management, Avilar Therapeutics in a trade secret case tied to Yale’s MODA platform.
Judgment formalized a combined USD 4 million award to Yale, Biohaven for willful, malicious misappropriation of the trade secret.
RA Capital also found to have breached a 2019 confidentiality agreement with Yale, driving USD 2 million of the total award.
Case stems from talks that ended in August 2019, followed by allegations RA Capital used shared technical information to build a competing program.
Post-trial motions remain possible, leaving the final outcome subject to further court review.
BHVN•
